Remove Biochemical Assays Remove Drug Development Remove Laboratories
article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

We often screen using a biochemical assay, but we can conduct cell-based screening as well. For fragment screening, we can screen with biophysical methods, such as thermal shift assays or, you may have heard about Surface Plasmon Resonance (SPR) which is a very sensitive biophysical technique used for fragment screening.

article thumbnail

Analysis Life Sciences Thank You Amid broader shift on LDT policy, FDA unveils pilot program for cancer drug-linked tests and diagnostics

Agency IQ

While the pilot has been in development for a while, the move comes as the FDA is looking towards a broader shift in its approach to LDTs. Further, footnote 7 in the document explains: “Examples of such clinical laboratory tests are commonly used and well understood biochemical assays (e.g.,

FDA 40
article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

BY RACHEL COE, MSC | APR 11, 2024 1:06 PM CDT Regulatory background: Product potency and assays As defined in statute , the FDA uses the term “potency” to refer to the “specific ability or capability” of a product to “effect a given result.” The new draft guidance can be broken into three main parts.